Literature DB >> 8013489

Fusarium infections in immunocompromised patients: case reports and literature review.

M Rabodonirina1, M A Piens, M F Monier, E Guého, D Fière, M Mojon.   

Abstract

Five cases are reported of Fusarium infection in patients with aplasia following chemotherapy of leukemia. The clinical signs, diagnosis and course of the infection during treatment are outlined and discussed in conjunction with the characteristics of other cases already reported in the literature. Sixty-three cases of Fusarium infection have been reported in immunocompromised patients, 44 cases since 1985. These included patients with hematological malignancies (58 cases), especially acute leukemia (43 cases). The main sites of infection were the skin (46 cases), blood (28 cases) and lungs (13 cases). The infection was mostly diagnosed by means of skin biopsy but also by means of positive blood cultures. Forty-three strains were identified, 19 of which were Fusarium solani. Amphotericin B treatment was given in 55 cases, often combined with other antifungal agents, leukocyte transfusions or granulocyte-macrophage-colony stimulating factor. The outcome was fatal in 36 of the 63 cases reported, often due to resistance of the strain to antifungal agents, particularly amphotericin B (20 of 33 strains tested). The most important risk factor seems to be profound and prolonged aplasia. Deep mycoses due to Fusarium species thus pose an important problem and are occurring in increasing numbers in immunocompromised patients. Treatment of these infections is difficult and the prognosis is poor.

Entities:  

Mesh:

Year:  1994        PMID: 8013489     DOI: 10.1007/bf01982190

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  43 in total

1.  Endemic panmyelotoxicosis in the Russian grain belt. I. The clinical aspects of alimentary toxic aleukia (ATA); a comprehensive review.

Authors:  C F MAYER
Journal:  Mil Surg       Date:  1953-09

2.  [Deep mycosis caused by Fusarium].

Authors:  J L Poirot; J P Laporte; E Gueho; A Verny; N C Gorin; A Najman; M Marteau; P Roux
Journal:  Presse Med       Date:  1985-12-21       Impact factor: 1.228

3.  Fusarium solani infection during treatment for acute leukemia.

Authors:  C T Cho; T S Vats; J T Lowman; J W Brandsberg; F E Tosh
Journal:  J Pediatr       Date:  1973-12       Impact factor: 4.406

Review 4.  Disseminated fusarial infection in the immunocompromised host.

Authors:  S E Richardson; R M Bannatyne; R C Summerbell; J Milliken; R Gold; S S Weitzman
Journal:  Rev Infect Dis       Date:  1988 Nov-Dec

5.  Invasive Fusarium infections in bone marrow transplant recipients.

Authors:  B R Blazar; D D Hurd; D C Snover; J W Alexander; P B McGlave
Journal:  Am J Med       Date:  1984-10       Impact factor: 4.965

6.  Fusarium infections in patients with hematologic malignancies.

Authors:  F R Schneller; S C Gulati; I B Cunningham; R J O'Reilly; H J Schmitt; B D Clarkson
Journal:  Leuk Res       Date:  1990       Impact factor: 3.156

7.  Catheter-associated fungemia caused by Fusarium chlamydosporum in a patient with lymphocytic lymphoma.

Authors:  T E Kiehn; P E Nelson; E M Bernard; F F Edwards; B Koziner; D Armstrong
Journal:  J Clin Microbiol       Date:  1985-04       Impact factor: 5.948

8.  Disseminated Fusarium moniliforme infection after allogeneic marrow transplantation.

Authors:  C H June; P G Beatty; H M Shulman; M G Rinaldi
Journal:  South Med J       Date:  1986-04       Impact factor: 0.954

9.  Fusarium meningoencephalitis in a child with acute leukemia.

Authors:  D P Agamanolis; D K Kalwinsky; C E Krill; S Dasu; B Halasa; P G Galloway
Journal:  Neuropediatrics       Date:  1991-05       Impact factor: 1.947

10.  Disseminated hyalohyphomycosis in a leukemic patient.

Authors:  T Matsuda; T Matsumoto
Journal:  Arch Dermatol       Date:  1986-10
View more
  15 in total

1.  Fungicidal activity of cecropin A.

Authors:  A J DeLucca; J M Bland; T J Jacks; C Grimm; T E Cleveland; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

2.  Successful outcome of treatment of a disseminated infection due to Fusarium dimerum in a leukemia patient.

Authors:  Valérie Letscher-Bru; France Campos; Jocelyn Waller; Raoul Randriamahazaka; Ermanno Candolfi; Raoul Herbrecht
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  Cutaneous Fusarium infection in a renal transplant recipient: a case report.

Authors:  John S Banerji; Chandra Singh J
Journal:  J Med Case Rep       Date:  2011-05-25

4.  Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan.

Authors:  T Yamazaki; H Kume; S Murase; E Yamashita; M Arisawa
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

5.  Treatment of murine fusariosis with SCH 56592.

Authors:  M Lozano-Chiu; S Arikan; V L Paetznick; E J Anaissie; D Loebenberg; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

6.  Invasive infection with Fusarium chlamydosporum in a patient with aplastic anemia.

Authors:  B H Segal; T J Walsh; J M Liu; J D Wilson; K J Kwon-Chung
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

7.  Recurrence of Fusarium solani abscess formation in an otherwise healthy patient.

Authors:  H S Leu; A Y Lee; T T Kuo
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

Review 8.  Opportunistic fusarial infections in humans.

Authors:  J Guarro; J Gené
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-09       Impact factor: 3.267

9.  Fungal lethality, binding, and cytotoxicity of syringomycin-E.

Authors:  A J De Lucca; T J Jacks; J Takemoto; B Vinyard; J Peter; E Navarro; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

10.  Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis.

Authors:  Montserrat Ortoneda; Javier Capilla; Francisco J Pastor; Isabel Pujol; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.